摘要
目的分析阿托伐他汀联合曲美他嗪对冠心病患者临床疗效及炎性因子水平的影响。方法选取2018年1月~2019年1月本院收治80例冠心病患者,将患者分为两组,对照组40例使用阿托伐他汀治疗,研究组40例在对照组基础上添加曲美他嗪治疗,对两组效果及炎性因子比较。结果研究组治疗总有效率为97.50%,明显高于对照组77.50%,差异比较具统计学意义;且研究组患者治疗后TNF-α与hsCRP水平分别为(96.74±21.08)ng/mL、(5.64±1.70)mg/L,明显优于对照组,差异比较具统计学意义(p<0.05)。结论临床将阿托伐他汀联合曲美他嗪治疗冠心病患者,不仅可以改善血清炎性因子水平,还能有效提高其治疗效果,值得临床推广使用。
Objective To analyze the clinical efficacy and inflammatory factors of atorvastatin combined with trimetazidine in patients with coronary heart disease.Methods The eighty patients with coronary heart disease were enrolled in our hospital from January 2018 to January 2019.The patients were divided into two groups.The 40 patients in the control group were treated with atorvastatin,and 40 patients in the study group were treated with trimetazidine on the basis of the control group.Then compare the therapeutic effects and inflammatory factors of the two groups.Results The total effective rate of the study group was 97.50%,which was significantly higher than that of the control group(77.50%).The difference was statistically significant.The TNF-αand hsCRP levels in the study group were(96.74±21.08)ng/mL,(5.64±1.70)mg/L,respectively.Which the level was significantly better than the control group,the difference was statistically significant(p<0.05).Conclusions The clinical treatment of atorvastatin combined with trimetazidine in patients with coronary heart disease can not only improve the level of serum inflammatory factors,but also effectively improve its therapeutic effect,which is worthy of clinical promotion.
作者
陆颖
Lu ying(Foshan First People's Hospital(Foshan Hospital Affiliated to Sun Yat-sen University)Foshan,Guangdong,528000,China)
出处
《临床心电学杂志》
2019年第5期340-342,共3页
Journal of Clinical Electrocardiology
关键词
曲美他嗪
阿托伐他汀
冠心病
临床疗效
炎性因子
trimetazidine
atorvastatin
coronary heart disease
clinical efficacy
inflammatory factor
